Compare Advance Auto Parts, Inc. (AAP) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Crispr Therapeutics AG — how do they compare? Advance Auto Parts, Inc. trades at $53.38 (market cap $3.19B), while Crispr Therapeutics AG trades at $53.84 (market cap $5.23B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Advance Auto Parts, Inc. pays a 1.89% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| AAP | CRSP | |
|---|---|---|
Market Cap | $3.19B | $5.23B |
Sector | Consumer Cyclical | Health |
52-Week High | $64.17 | $76.78 |
52-Week Low | $38.75 | $44.34 |
Enterprise Value | $5.47B | $3.65B |
Dividend Yield | 1.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $55.73, down 3.58% today, reflecting bearish technical signals amid mixed fundamentals. The company reported Q1 2026 EPS of $0.77, beating expectations, with revenue at $8.6 billion for 2025 but a slim net income margin of 0.51%. Recent news highlights restructuring efforts and AI-driven delivery initiatives to stabilize operations.
The outlook is cautious; while valuation ratios like P/S of 0.37 appear attractive, weak profitability and negative operating cash flow pose risks. Analyst consensus is mixed with a $61.30 price target, but high debt and competitive pressures require monitoring for sustained turnaround progress.
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
